Ricerc@Sapienza

The effects of the patented treated-yeast, Saccharomyces cerevisiae, a
probiotic suspension which was shown earlier to present
neuroprotective and neurorestorative properties, upon allergies
presented by a group (n=8) of patients, that were compared with a
matched group of patients administered untreated yeast cells (n=8).
Treated yeast cells were subjected to millimeter-wave exposure as
outlined in patented documents. The patients who administered
themselves treated Milmed, over periods extending from four-tothirteen weeks, completed subjective self-report ratings of their allergy
symptoms that indicated marked ameliorative effects; additionally,
they rated their general health situations to be markedly improved.
Those patients who had taken the untreated yeast did not report these
improvements. Correlational analyses between the number of weeks
treated Milmed was taken by patients and (i) alleviation of allergy
symptoms, and (ii) improvement in general health status, indicated
significant relationships in each case. The significant correlations
between symptom improvements and general health status, on one hand, and the number of weeks
treated Milmed was ingested imply that complete treatments are required for the optimal therapeutic
benefits. As observed previously, 8-to-13-week episodes of treated Milmed self-administration provides
a lasting amelioration from allergy symptoms and an improved general health status.